JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2001; 38:1662-1667
© 2001 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Khan, B. V.
Right arrow Articles by Parthasarathy, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Khan, B. V.
Right arrow Articles by Parthasarathy, S.

CLINICAL STUDY

Irbesartan, an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery disease

Bobby V. Khan, MD, PhD*,* {dagger} {ddagger}, Sushant Navalkar, MD* {dagger} {ddagger}, Qamar A. Khan, MD, FACC* {ddagger}, Syed T. Rahman, MD* {ddagger} and Sampath Parthasarathy, PhD{dagger} {ddagger}

* Emory University School of Medicine, Division of Cardiology, Atlanta Center for Vascular Research, Atlanta, Georgia, USA
{dagger} Emory University School of Medicine, Division of Gynecology/Obstetrics and, Atlanta Center for Vascular Research, Atlanta, Georgia, USA
{ddagger} Emory University School of Medicine, Division of Atlanta Center for Vascular Research, Atlanta, Georgia, USA

Manuscript received January 23, 2001; revised manuscript received July 13, 2001, accepted August 9, 2001.

* Reprint requests and correspondence: Dr. Bobby V. Khan, Emory University School of Medicine, Division of Cardiology, 69 Butler Street SE, #C233, Atlanta, Georgia 30303 USA
bkhan{at}emory.edu

OBJECTIVES

The aim of this study was to determine the effect of angiotensin II type 1 (AT1) receptor antagonists on pro-oxidant species observed in the pathogenesis of atherosclerosis. Parameters such as low-density lipoprotein (LDL) susceptibility, monocyte binding capacity, superoxide generation and lipid peroxidation were examined in the presence of the AT1 receptor antagonist irbesartan.

BACKGROUND

Low-density lipoprotein oxidation is a key component in the process of atherogenesis. This modification may involve various mechanisms, including changes in nitric oxide levels and superoxide levels. Additionally, compounds that suppress these mechanisms may retard or inhibit the pathogenesis of atherosclerosis.

METHODS

Forty-seven patients with documented coronary artery disease were treated with irbesartan for a 12-week period. Patients were randomized to receive irbesartan or placebo. Lipid peroxidation, superoxide levels, monocyte binding and LDL oxidation were measured at 0, 4 and 12 weeks. Findings were statistically evaluated by two-way repeated measures analysis of variance with p < 0.05 being significant.

RESULTS

Treatment with irbesartan significantly decreased the pro-oxidative environment seen in our study population. Lag time for LDL oxidation increased 32% at 12 weeks, suggesting an increased resistance of LDL modification in the serum. Thiobarbituric acid reactive substances activity indicated that lipid peroxidation decreased by 36% in comparison to placebo. In addition, superoxide levels and monocyte-binding capacity were also significantly reduced in coronary artery disease patients receiving irbesartan.

CONCLUSIONS

Our results indicate that irbesartan may suppress the atherosclerotic process by inhibiting the intravascular oxidative state and the production of reactive oxygen species, compounds that may cause damage to the vasculature.

Abbreviations and Acronyms
  ACE = angiotensin-converting enzyme
  ANOVA = analysis of variance
  AT1 = angiotensin II type 1 receptor
  BP = blood pressure
  CAD = coronary artery disease
  13-HPODE = 13 hydroperoxy linoleic acid
  LDL = low-density lipoprotein
  MI = myocardial infarction
  NO = nitric oxide
  ox-LDL = oxidized low-density lipoprotein
  PTCA = percutaneous transluminal coronary angioplasty
  TBARS = thiobarbituric acid reactive substances




This article has been cited by other articles:


Home page
J. Nutr.Home page
M. B. Zemel and X. Sun
Dietary Calcium and Dairy Products Modulate Oxidative and Inflammatory Stress in Mice and Humans
J. Nutr., June 1, 2008; 138(6): 1047 - 1052.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
T. M. Paravicini and R. M. Touyz
NADPH Oxidases, Reactive Oxygen Species, and Hypertension: Clinical implications and therapeutic possibilities
Diabetes Care, February 1, 2008; 31(Supplement_2): S170 - S180.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
E. Grossman
Does Increased Oxidative Stress Cause Hypertension?
Diabetes Care, February 1, 2008; 31(Supplement_2): S185 - S189.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
U. Singh, J. Tabibian, S. K. Venugopal, S. Devaraj, and I. Jialal
Development of an In Vitro Screening Assay to Test the Antiinflammatory Properties of Dietary Supplements and Pharmacologic Agents
Clin. Chem., December 1, 2005; 51(12): 2252 - 2256.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
L M Biasucci, M Lombardi, M Piro, G Di Giannuario, G Liuzzo, and F Crea
Irbesartan significantly reduces C reactive protein concentrations after 1 month of treatment in unstable angina
Heart, May 1, 2005; 91(5): 670 - 671.
[Full Text] [PDF]


Home page
CirculationHome page
D. Fliser, K. Buchholz, H. Haller, and for the EUropean Trial on Olmesartan and Pravastat
Antiinflammatory Effects of Angiotensin II Subtype 1 Receptor Blockade in Hypertensive Patients With Microinflammation
Circulation, August 31, 2004; 110(9): 1103 - 1107.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
B. V. Khan, S. Sola, W. B. Lauten, R. Natarajan, W. C. Hooper, R. G. Menon, S. Lerakis, and T. Helmy
Quinapril, an ACE Inhibitor, Reduces Markers of Oxidative Stress in the Metabolic Syndrome
Diabetes Care, July 1, 2004; 27(7): 1712 - 1715.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
H. V. Anderson
Angiotensin-converting enzyme inhibitors: ischemia is not the correct measure of benefit
J. Am. Coll. Cardiol., December 17, 2003; 42(12): 2060 - 2062.
[Full Text] [PDF]


Home page
HypertensionHome page
M.-S. Zhou, A. G. Adam, E. A. Jaimes, and L. Raij
In Salt-Sensitive Hypertension, Increased Superoxide Production Is Linked to Functional Upregulation of Angiotensin II
Hypertension, November 1, 2003; 42(5): 945 - 951.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J. M. Proudfoot, K. D. Croft, I. B. Puddey, and L. J. Beilin
Angiotensin II Type 1 Receptor Antagonists Inhibit Basal As Well As Low-Density Lipoprotein and Platelet-Activating Factor-Stimulated Human Monocyte Chemoattractant Protein-1
J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 846 - 853.
[Abstract] [Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2001 by the American College of Cardiology Foundation.